Area of research
Infectious Diseases · Molecular Biology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Genomics and Phylogenetic Studies, and RNA and protein synthesis mechanisms.
A potent pan-sarbecovirus neutralizing antibody resilient to epitope diversification
Recommendations for Uniform Variant Calling of SARS-CoV-2 Genome Sequence across Bioinformatic Workflows.
Resistance analysis in the phase III COMET-TAIL study: treatment of COVID-19 with intramuscular or intravenous sotrovimab
A pan-influenza antibody inhibiting neuraminidase via receptor mimicry
A pan-influenza antibody inhibiting neuraminidase via receptor mimicry.
Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE study.
Author Correction: A pan-influenza antibody inhibiting neuraminidase via receptor mimicry.
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
Predicting the mutational drivers of future SARS-CoV-2 variants of concern
Predicting the mutational drivers of future SARS-CoV-2 variants of concern.
Towards increased accuracy and reproducibility in SARS-CoV-2 next generation sequence analysis for public health surveillance
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Broad betacoronavirus neutralization by a stem helix–specific human antibody
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern.
Broad betacoronavirus neutralization by a stem helix-specific human antibody.
Broad sarbecovirus neutralization by a human monoclonal antibody
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Predicting the mutational drivers of future SARS-CoV-2 variants of concern
Structural basis for broad sarbecovirus neutralization by a human monoclonal antibody
Antibodies to the SARS-CoV-2 receptor-binding domain that maximize breadth and resistance to viral escape
Transfer transcriptomic signatures for infectious diseases.
Antibody therapy reverses biological signatures of COVID-19 progression
Ranking of non-coding pathogenic variants and putative essential regions of the human genome
Ranking of non-coding pathogenic variants and putative essential regions of the human genome.
BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment